论文部分内容阅读
目的验证新一代片段分析技术(advanced fragment analysis,AFA),对HCV基因分型及白细胞介素28B的2个SNP位点多态位点检测的可靠性,并探讨其在聚乙二醇干扰素联合利巴韦林抗HCV的疗效预判中的意义。方法收集132例慢性丙型肝炎患者外周血样本。同时随访1年~2.5年,并将患者分成2组,比较HCV不同基因型以及携带不同SNP位点患者在2组中的差异。结果 AFA对样本进行分型检测,与Sanger测序法比较,准确性达到100%,随访发现感染HCV亚型为1b的患者、或者rs12979860 CT型、或rs8099917 TG型患者干扰素治疗后,复发概率高。结论AFA法检测丙型肝炎病毒基因分型及rs12979860和rs8099917位点多态性,具有准确性好、通量高、操作简便等特点,适合于临床推广应用。
Objective To validate a new generation of advanced fragment analysis (AFA) to test the reliability of HCV genotyping and polymorphism detection of two SNP loci in interleukin-28B and explore its possible role in pegylated interferon The significance of combined ribavirin anti-HCV in predicting the curative effect. Methods Peripheral blood samples from 132 patients with chronic hepatitis C were collected. At the same time, follow-up was 1 year to 2.5 years, and the patients were divided into two groups. The differences of HCV genotypes and patients with different SNP loci in the two groups were compared. Results The AFA was used to detect the samples. The accuracy was 100% compared with Sanger sequencing. Follow-up found that patients with HCV subtype 1b or rs12979860 CT or rs8099917 TG had higher relapse probability after interferon treatment . Conclusion The AFA method can detect genotypes of hepatitis C virus and rs12979860 and rs8099917 locus polymorphisms, which has the advantages of good accuracy, high throughput and easy operation. It is suitable for clinical application.